| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/24/2003 | CA2461170A1 Peptidyl ketones as inhibitors of dpiv |
| 04/24/2003 | CA2460685A1 Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 04/24/2003 | CA2460574A1 Enteric coated tablets comprising mycophenolic acid or mycophenolate salt |
| 04/24/2003 | CA2460132A1 Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent |
| 04/24/2003 | CA2459572A1 Composition comprising a lactobacillus pentosus strain and uses thereof |
| 04/24/2003 | CA2454578A1 Modified human thymic stromal lymphopoietin |
| 04/23/2003 | EP1304379A2 Humanised antibody against CD18 |
| 04/23/2003 | EP1304378A1 ARL-2 for fertility control |
| 04/23/2003 | EP1304322A2 Carboxylic acid compound and use thereof |
| 04/23/2003 | EP1304101A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications |
| 04/23/2003 | EP1303632A2 Galactomannan oligosaccharides and methods for the production and use thereof |
| 04/23/2003 | EP1303625A2 Alpha-msh related compounds and methods of use |
| 04/23/2003 | EP1303610A2 Extracellular matrix protein |
| 04/23/2003 | EP1303607A2 High affinity soluble interleukin-18 receptor |
| 04/23/2003 | EP1303604A2 Mammalian receptor proteins; related reagents and methods |
| 04/23/2003 | EP1303600A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 04/23/2003 | EP1303540A2 Multi-specific reagent for selective stimulation of cell surface receptors |
| 04/23/2003 | EP1303535A2 Protein complex serving as a vehicle for orally administerable medicaments |
| 04/23/2003 | EP1303533A2 Chimeric peptide immunogens, their preparation and use |
| 04/23/2003 | EP1303517A1 Indoloquinazolinones |
| 04/23/2003 | EP1303513A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| 04/23/2003 | EP1303512A1 Process for preparing arylacetylaminothiazoles |
| 04/23/2003 | EP1303508A1 Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
| 04/23/2003 | EP1303507A1 Pyrimidine derivatives |
| 04/23/2003 | EP1303506A1 6-heteroarylphenanthridines |
| 04/23/2003 | EP1303496A1 Pyrimidine derivatives |
| 04/23/2003 | EP1303492A2 Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
| 04/23/2003 | EP1303490A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 04/23/2003 | EP1303488A1 Piperidine compounds for use as ccr-3 inhibitors |
| 04/23/2003 | EP1303486A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 04/23/2003 | EP1303485A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 04/23/2003 | EP1303303A1 Immunomodulatory human mhc class ii antigen-binding polypeptides |
| 04/23/2003 | EP1303302A2 Use of strains of the parapox ovis virus against organ fibrosis |
| 04/23/2003 | EP1303299A1 Compositions and methods for enhancing immunogenicity of antigens |
| 04/23/2003 | EP1303293A2 Apo-2l receptor agonist and cpt-11 synergism |
| 04/23/2003 | EP1303292A1 Chemokine conjugates |
| 04/23/2003 | EP1303290A1 Small peptides and methods for downregulation of ige |
| 04/23/2003 | EP1303286A2 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 04/23/2003 | EP1303265A2 Use of cox-2 inhibitors for preventing immunodeficiency |
| 04/23/2003 | EP1257537A4 Therapeutic morpholino-substituted compounds |
| 04/23/2003 | EP1250055A4 Immune modulation with death receptor-induced apoptosis |
| 04/23/2003 | EP1237892B1 Method for producing epinastine hydrochloride in the high-melting crystal modification |
| 04/23/2003 | EP1220863B1 Purine derivatives |
| 04/23/2003 | EP1133483B1 Il-5 inhibiting 6-azauracil derivatives |
| 04/23/2003 | EP1114046B1 Interleukin-5 inhibiting 6-azauracil derivatives |
| 04/23/2003 | EP1045690B1 Benzenesulfonamide inhibitors of pde-iv and their therapeutic use |
| 04/23/2003 | EP1028738B1 Use of cytokines and mitogens to inhibit pathological immune responses |
| 04/23/2003 | EP1027359B1 Monocyclic l-nucleosides, analogs and uses thereof |
| 04/23/2003 | EP0861266B1 Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them |
| 04/23/2003 | EP0840618B1 Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies |
| 04/23/2003 | CN1413258A Invasive bacterial vectors for expressing alphavirus replicons |
| 04/23/2003 | CN1413250A Method of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| 04/23/2003 | CN1413241A Dry compositions containing hydrophobic amino acid |
| 04/23/2003 | CN1413213A Azaindoles |
| 04/23/2003 | CN1413211A Substituted 1,3,4-oxadiazoles and method of producing TNF-alpha levels |
| 04/23/2003 | CN1413210A Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| 04/23/2003 | CN1413207A 5-membered ring heterocyclic compounds with nitrogen |
| 04/23/2003 | CN1413206A Non peptide tachykinin receptor antagonists |
| 04/23/2003 | CN1413198A Methods and compositions utilizing quianzolinones |
| 04/23/2003 | CN1413193A Nitrile derivatives as cathepsin K inhibitors |
| 04/23/2003 | CN1413192A Substituted indole mannich bases |
| 04/23/2003 | CN1413186A Aminobenzophenones as inhibitors of IL-1 beta and TNF-alpha |
| 04/23/2003 | CN1413185A Substitued 1 and 2 naphthol mannich bases |
| 04/23/2003 | CN1413181A Novel hydronaphtalene compounds prepared by phodium catalyzed ring opening reaction in presence of phosphine ligand |
| 04/23/2003 | CN1413112A Nasal drops containing fused pyridazine derivatives |
| 04/23/2003 | CN1413109A Substituted acylhydroxamic acids and method of reducing TNF-alpha levels |
| 04/23/2003 | CN1413105A Novel method of treatment |
| 04/23/2003 | CN1413104A New (aminopropyl) methylphosphinic acids |
| 04/23/2003 | CN1412197A 17 peptide organic compound and its application |
| 04/23/2003 | CN1412181A Carboxylic acid derivative capable of inhibiting combination of integrin and its receptor |
| 04/23/2003 | CN1411869A Body-strengthening nutrient sour liquor, preparation method and application |
| 04/23/2003 | CN1411827A Capsule for curing acne |
| 04/23/2003 | CN1411809A Usage and composition of pyridine onium derivative for curing application |
| 04/23/2003 | CN1411800A Cosmetic composition and method |
| 04/23/2003 | CN1106387C PDEIV inhibiting 2-cyanoiminoimidazole derivatives |
| 04/23/2003 | CN1106202C Anti-aids immunomodulator complex |
| 04/22/2003 | US6552223 N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them |
| 04/22/2003 | US6552216 Molecular model for VLA-4 inhibitors |
| 04/22/2003 | US6552202 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
| 04/22/2003 | US6552200 Intermediates useful for the preparation of antihistaminic piperidine derivatives |
| 04/22/2003 | US6552192 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof |
| 04/22/2003 | US6552188 Unsymmetrical cyclic diamine compound |
| 04/22/2003 | US6552183 Moncyclic L-nucleosides analogs |
| 04/22/2003 | US6552168 Inhibition of apoptosis via attenuation of caspase activity should therefore be useful in the treatment of human diseases where inappropriate apoptosis is prominent or contributes to disease pathogenesis |
| 04/22/2003 | US6552088 Biphenyl derivatives |
| 04/22/2003 | US6552083 Administering therapeutically effective amount of N-(3,4-dimethoxycinnamoyl)anthranilic acid or its salt |
| 04/22/2003 | US6552036 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 04/22/2003 | US6552029 For therapy of rheumatoid arthritis, psoriasis, graft v. host disease, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, complications following percutaneous transluminal coronary angioplasty, thrombosis |
| 04/22/2003 | US6552019 Inhibitors of p38 |
| 04/22/2003 | US6552010 Treatment of SLE with dehydroepiandrosterone |
| 04/22/2003 | US6552006 Treating intracellular parasitic infection in humans; administer to human immunomodulatory nucleic acid and parasitide, monitor humans response, decrease in parasite replication indicates infection preventative |
| 04/22/2003 | US6551989 Preventing airway mucus production by administration of EGF-R antagonists |
| 04/22/2003 | US6551810 Polypeptide retains the ability to dephosphorylate an activated MAP-kinase |
| 04/22/2003 | US6551626 Composition containing pyrrolizidine-alkaloid-free petasites |
| 04/22/2003 | US6551600 Immunological adjuvant compounds compositions and methods of use thereof |
| 04/22/2003 | US6551599 Monoclonal antibodies against campylobacter jejuni and campylobacter coli outer membrane antigens |
| 04/22/2003 | US6551596 Fractions of Chlorella extract containing polysaccharide having immunomodulating properties |
| 04/22/2003 | CA2068630C Use of protein c or activated protein c |
| 04/22/2003 | CA1341427C Variants of immunoglobulin gene superfamily member |
| 04/18/2003 | WO2002030457A2 Microbes having an attenuating mutation comprising a transcription terminator |